ZFIN Image: Frese et al., 2015, Fig. 2

Image

Figure Caption

Fig. 2

Knockdown of rbfox1 leads to cardiomyopathy and heart failure. (A–C) Lateral view of MO-control- and MO1- and MO2-rbfox1-injected embryos. After injection of 3ng MO1-rbfox1, 85% (D) and MO2-rbfox1, 72% (E) of morphants embryos develop cardiomyopathy and heart failure. Results are mean±s.d. (n=3). (F) cDNA analysis of rbfox1 morphants after injection of MO2-rbfox1 shows skipping of exon 6 (198-bp product) compared to a product including exon 6 (259bp product) in control-treated embryos. Sanger sequencing reveals that exon 6 is completely excluded, predictably leading to a frame shift of the coding sequence and premature stop in exon 7. (H,I) Fractional shortening (FS) of the ventricular chamber of MO-control- and MO1-rbfox1-injected embryos measured at the indicated developmental stages. Fractional shortening is significantly reduced in rbfox1 morphants after 48hpf and further declines at 96hpf. Results are mean±s.d. (n=10).

Figure Data

Phenotype details

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ J. Cell Sci.